Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6043 vs Chemotherapy as First-Line Treatment in Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
NCT07879911Phase 3Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Nov 2026
- Primary completion
- Nov 2028
01
Overview
A Phase 3 trial of SYS6043 in triple-negative breast cancer (TNBC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
SYS6043
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07879911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07879911.